Effects of the Ad5 upstream E1 region and gene products of heterologous promoters

Journal of Gene Medicine

Volumn 7, Issue 10, 2005, Pages 1356-1366

  Hoffmann, Dennis ^a   Jogler, Christian ^a   Wildner, Oliver ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Adenovirus; Heterologous promoters; Promoter specificity

Indexed keywords

ADENOVIRUS VECTOR; CIS ACTING ELEMENT; CYCLOOXYGENASE 2; E1A PROTEIN; GENE PRODUCT; KI 67 ANTIGEN; LUCIFERASE; MIDKINE; PLASMID DNA; PLASMID VECTOR; POLYADENYLIC ACID; TRANSCRIPTION FACTOR E2F1; VIRUS PROTEIN;

ADENOVIRUS 5; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA FLANKING REGION; ENHANCER REGION; GENE CASSETTE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SIMIAN VIRUS 40; TRANSCRIPTION INITIATION SITE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENE; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CELL CYCLE; CELL LINE; CYCLOOXYGENASE 2; CYTOPATHOGENIC EFFECT, VIRAL; E2F1 TRANSCRIPTION FACTOR; GENES, REPORTER; HUMANS; KI-67 ANTIGEN; LUCIFERASES; PLASMIDS; PROMOTER REGIONS (GENETICS); REPLICATION ORIGIN; TRANSCRIPTION FACTORS;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MIRIDAE; SIMIAN VIRUS 40; VIBRIO PHAGE NT-1;

EID: 27644535713     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.771     Document Type: Article

References (78)

1. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996; 334: 1185-1187.
2. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene deliery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
3. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994; 1: 170-175.
4. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res 1996; 56: 5638-5646.
5. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55: 5283-5287.
6. Wills KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther 1995; 2: 191-197.
7. Arbuthnot PB, Bralet MP, Le JC, Dedieu JF, Perricaudet M, Brechot C. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996; 7: 1503-1514.
8. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96: 2775-2782.
9. Rothmann T, Katus HA, Hartong R, Perricaudet M, Franz WM. Heart muscle-specific gene expression using replication defective recombinant adenovirus. Gene Ther 1996; 3: 919-926.
10. Larochelle N, Lochmuller H, Zhao J, et al. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer. Gene Ther 1997; 4: 465-472.
11. Connelly S, Gardner JM, McClelland A, Kaleko M. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 1996; 7: 183-195.
12. Babiss LE, Freedman JM, Darnell JE Jr. Cellular promoters incorporated into the adenovirus genome: effects of viral regulatory elements on transcription rates and cell specificity of albumin and beta-globin promoters. Mol Cell Biol 1986; 6: 3798-3806.
13. Kim S, Lin H, Barr E, Chu L, Leiden JM, Parmacek MS. Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest 1997; 100: 1006-1014.
14. Ring CJ, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther 1996; 3: 1094-1103.
15. Imler JL, Dupuit F, Chartier C, et al. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Ther 1996; 3: 49-58.
16. Shi Q, Wang Y, Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther 1997; 8: 403-410.
17. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci U S A 1992; 89: 2581-2584.
18. Hearing P, Shenk T. The adenovirus type 5 E1A enhancer contains two functionally distinct domains: one is specific for E1A and the other modulates all early units in cis. Cell 1986; 45: 229-236.
19. Vassaux G, Hurst HC, Lemoine NR. Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther 1999; 6: 1192-1197.
20. Buvoli M, Langer SJ, Bialik S, Leinwand LA. Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors. Gene Ther 2002; 9: 227-231.
21. Yamamoto M, Davydova J, Takayama K, Alemany R, Curiel DT. Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted. J Virol 2003; 77: 1633-1637.
22. Hearing P, Shenk T. The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element. Cell 1983; 33: 695-703.
23. Grable M, Hearing P. cis and trans requirements for the selective packaging of adenovirus type 5 DNA. J Virol 1992; 66: 723-731.
24. Hatfield L, Hearing P. Redundant elements in the adenovirus type 5 inverted terminal repeat promote bidirectional transcription in vitro and are important for virus growth in vivo. Virology 1991; 184: 265-276.
25. Hatfield L, Hearing P. The NFIII/OCT-1 binding site stimulates adenovirus DNA replication in vivo and is functionally redundant with adjacent sequences. J Virol 1993; 67: 3931-3939.
26. Miralles VJ, Cortes P, Stone N, Reinberg D. The adenovirus inverted terminal repeat functions as an enhancer in a cell-free system. J Biol Chem 1989; 264: 10 763-10 772.
27. Steinwaerder DS, Lieber A. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther 2000; 7: 556-567.
28. Chung JH, Bell AC, Felsenfeld G. Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci U S A 1997; 94: 575-580.
29. Friedman JM, Babiss LE, Clayton DF, Darnell JE Jr. Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression. Mol Cell Biol 1986; 6: 3791-3797.
30. Naylor LH. Reporter gene technology: the future looks bright. Biochem Pharmacol 1999, 58: 749-757.
31. Uehara K, Matsubara S, Kadomatsu K, Tsutsui J, Muramatsu T. Genomic structure of human midkine (MK), a retinoic acid-responsive growth/differentiation factor. J Biochem (Tokyo) 1992; 111: 563-567.
32. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 2000; 275: 28 028-28 032.
33. Duchrow M, Schluter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 1996; 29: 1-12.
34. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994; 8: 1514-1525.
35. Levitt N, Briggs D, Gil A, Proudfoot NJ. Definition of an efficient synthetic poly(A) site. Genes Dev 1989; 3: 1019-1025.
36. Carswell S, Alwine JC. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol 1989; 9: 4248-4258.
37. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Plainview, NY, 1989.
38. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95: 2509-2514.
39. Wildner O, Morris JC. The role of the E1B 55 kDa gene in oncolytic adenoviral vectors expressing HSV-tk: assessment of anti-tumor efficacy and toxicity. Cancer Res 2000; 60: 4167-4174.
40. Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991; 11: 5848-5859.
41. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WF. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
42. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
43. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
44. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
45. Graham FL, Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
46. Hung DT, Jamison TF, Schreiber SL. Understanding and controlling the cell cycle with natural products. Chem Biol 1996; 3: 623-639.
47. Available: http://cbrc.jp/research/db/TFSEARCH.html.
48. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998; 26: 362-367.
49. Glinghammar B, Rafter J. Colonic luminal contents induce cyclooxygenase 2 transcription in human colon carcinoma cells. Gastroenterology 2001; 120: 401-410.
50. Shi CX, Hitt M, Ng P, Graham FL. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther 2002; 13: 211-224.
51. Thompson JF, Hayes LS, Lloyd DB. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene 1991; 103: 171-177.
52. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987; 7: 725-737.
53. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 808-811.
54. Merli C, Bergstrom DE, Cygan JA, Blackman RK. Promoter specificity mediates the independent regulation of neighboring genes. Genes Dev 1996; 10: 1260-1270.
55. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. Science 1998; 281: 61-63.
56. Pajalunga D, Tognozzi D, Tiainen M, et al. E2F activates late-G1 events but cannot replace E1A in inducing S phase in terminally differentiated skeletal muscle cells. Oncogene 1999; 18: 5054-5062.
57. Howe JA, Mymryk JS, Egan C, Branton PE, Bayley ST. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc Natl Acad Sci U S A 1990; 87: 5883-5887.
58. Wang HG, Draetta G, Moran E. E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol Cell Biol 1991; 11: 4253-4265.
59. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
60. Liu F, Green MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 1990; 61: 1217-1224.
61. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991; 67: 377-388.
62. Yoshida K, Narita M, Fujinaga K. Binding sites of HeLa cell nuclear proteins on the upstream region of adenovirus type 5 E1A gene. Nucleic Acids Res 1989; 17: 10 015-10 034.
63. Bruder JT, Hearing P. Cooperative binding of EF-1A to the E1A enhancer region mediates synergistic effects on E1A transcription during adenovirus infection. J Virol 1991; 65: 5084-5087.
64. Hearing P, Shenk T. Sequence-independent autoregulation of the adenovirus type 5 E1A transcription unit. Mol Cell Biol 1985; 5: 3214-3221.
65. Johnson JS, Osheim YN, Xue Y, et al. Adenovirus protein VII condenses DNA, represses transcription, and associates with transcriptional activator E1A. J Virol 2004; 78: 6459-6468.
66. Swenarchuk L, Harakidas P, Cochrane A. Regulated expression of HIV-1 Rev function in mammalian cell lines. Can J Microbiol 1999; 45: 480-490.
67. Horwitz MS. Adenoviruses. In Fields Virology, Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins: Philadelphia, 2001; 2301-2326.
68. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
69. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of HSV- tk. Cancer Res 1999; 59: 410-413.
70. Wildner O, Morris JC, Vahanian NN, Ford HJ, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57-62.
71. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
72. Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F- responsive adenoviral vector. Nat Med 1997; 3: 1145-1149.
73. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
74. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
75. Hitt MM, Graham FL. Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 1990; 179: 667-678.
76. Shenk T. Adenoviridea. In Fields' Virology, Fields BN, Knipe DM, Howley PM (eds). Lippincott-Raven: Philadelphia, 1996; 2111-2148.
77. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
78. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994; 8: 1514-1525.